Search

Purpose: The purpose of this work was to evaluate the absorbed dose to Al{sub 2}O{sub 3} dosimeter at various depths of water phantom in radiotherapy photon beams by Monte Carlo simulation and evaluate the beam quality dependence. Methods: The simulations were done using EGSnrc. The cylindrical Al{sub 2}O{sub 3} dosimeter ({Phi}4 mmx1 mm) was placed at the central axis of the water phantom ({Phi}16 cmx16 cm) at depths between 0.5 and 8 cm. The incident beams included monoenergetic photon beams ranging from 1 to 18 MeV, {sup 60}Co {gamma} beams, Varian 6 MV beams using phase space files based on a full simulation of the linac, and Varian beams between 4 and 24 MV using Mohan's spectra. The absorbed dose to the dosimeter and the water at the corresponding position in the absence of the dosimeter, as well as absorbed dose ratio factor f{sub md}, was calculated. Results: The results show that f{sub md} depends obviously on the photon energy at the shallow depths. However, as the depth increases, the change in f{sub md} becomes small, beyond the buildup region, the maximum discrepancy of f{sub md} to the average value is not more than 1%. Conclusions: These simulation results confirmmore » the use of Al{sub 2}O{sub 3} dosimeter in radiotherapy photon beams and clearly indicate that more attention should be paid when using such a dosimeter in the buildup region of high-energy radiotherapy photon beams.« less

In nasopharyngeal cancer (NPC) intracavitary brachytherapy, an anatomical dose reference point (in line with that for gynecology work), e.g., at the sphenoid floor, is more precise than the empirical point of 1 cm from the source. However, such increases of the single-source-plan treatment distances may deliver excessive doses inferiorly, to the soft palate. As shielding may help, its efficacy was studied by Monte Carlo simulations in water for 20 and 30 mm diameter spherical NP applicators (representing extremes of sizes for the small NP cavity), with/without lead shielding inferiorly, using a single linear Ir-192, 2 mm steps, equal dwell times for 5 (5DP) and 9 dwell positions (9DP). Dose reductions of the selected points of interest ranged from 1.2% to 40.5% for the 20 mm shielded applicator and a range of 2.9% to 17.9%, for the 30 mm shielded applicator. Dose volume histograms of the “region of interest” (ROI)—a cuboid of 4 × 4 × 0.5 cm 3 at the most inferior aspect of the applicator, also differed significantly. The highest doses of the 50% ( D 50 ) and 20% ( D 20 ) volumes of ROI (for 5DP and 9DP plans) were reduced by 11.9% to 17.9% for the 20 mm applicator and a range of 9.0% to 11.5% for the 30 mm shielded applicator. Doses in unshielded directions were insignificantly changed, for example, with a 20 mm applicator simulated in a 5DP plan, the dose distribution close to the source in the unshielded direction has less than 4% difference at the 50% isodose relative to the dose prescription point. For the 30 mm shielded applicator, despite smaller dose reduction percentages, a more pronounced effective dose reduction was obtained than nominal values when considering radiobiological equivalent doses. Our system was demonstrated to be ready for clinical assessment.

The purpose of this work was to evaluate the absorbed dose to AL2O3 dosimeter at various depths of water phantom in radiotherapy photon beams by Monte Carlo simulation and evaluate the beam quality dependence.The simulations were done using EGSnrc. The cylindrical Al2O3 dosimeter (Phi4 mm x 1 mm) was placed at the central axis of the water phantom (Phi16 cm x 16 cm) at depths between 0.5 and 8 cm. The incident beams included monoenergetic photon beams ranging from 1 to 18 MeV, 60Co gamma beams, Varian 6 MV beams using phase space files based on a full simulation of the linac, and Varian beams between 4 and 24 MV using Mohan's spectra. The absorbed dose to the dosimeter and the water at the corresponding position in the absence of the dosimeter, as well as absorbed dose ratio factor fmd, was calculated.The results show that fmd depends obviously on the photon energy at the shallow depths. However, as the depth increases, the change in fmd becomes small, beyond the buildup region, the maximum discrepancy of fmd to the average value is not more than 1%.These simulation results confirm the use of Al2O3 dosimeter in radiotherapy photon beams and clearly indicate that more attention should be paid when using such a dosimeter in the buildup region of high-energy radiotherapy photon beams.

In nasopharyngeal cancer (NPC) intracavitary brachytherapy, an anatomical dose reference point (in line with that for gynecology work), e.g., at the sphenoid floor, is more precise than the empirical point of 1 cm from the source. However, such increases of the single-source-plan treatment distances may deliver excessive doses inferiorly, to the soft palate. As shielding may help, its efficacy was studied by Monte Carlo simulations in water for 20 and 30 mm diameter spherical NP applicators (representing extremes of sizes for the small NP cavity), with/without lead shielding inferiorly, using a single linear Ir-192, 2 mm steps, equal dwell times for 5 (5DP) and 9 dwell positions (9DP). Dose reductions of the selected points of interest ranged from 1.2% to 40.5% for the 20 mm shielded applicator and a range of 2.9% to 17.9%, for the 30 mm shielded applicator. Dose volume histograms of the "region of interest" (ROI)-a cuboid of 4 x 4 x 0.5 cm3 at the most inferior aspect of the applicator, also differed significantly. The highest doses of the 50% (D50) and 20% (D20) volumes of ROI (for 5DP and 9DP plans) were reduced by 11.9% to 17.9% for the 20 mm applicator and a range of 9.0% to 11.5% for the 30 mm shielded applicator. Doses in unshielded directions were insignificantly changed, for example, with a 20 mm applicator simulated in a 5DP plan, the dose distribution close to the source in the unshielded direction has less than 4% difference at the 50% isodose relative to the dose prescription point. For the 30 mm shielded applicator, despite smaller dose reduction percentages, a more pronounced effective dose reduction was obtained than nominal values when considering radiobiological equivalent doses. Our system was demonstrated to be ready for clinical assessment.